NanoString’s GeoMx Digital Spatial Profiling Platform Reveals Insights Into the Immune Landscape of Cancer in Publication in the Journal Cell

Rhea-AI Summary

NanoString Technologies (NASDAQ: NSTG) announced the publication of a peer-reviewed study in the journal Cell, showcasing the use of its GeoMx^® Digital Spatial Profiler (DSP) in colorectal cancer research. The study, led by researchers from the Broad Institute, examined interactions between tumor and immune cells in colorectal cancer samples. Using advanced techniques, the study revealed spatial transcriptional regulation crucial for understanding immune-tumor dynamics. NanoString's DSP aids in high-throughput RNA and protein profiling, with over 60 publications validating its applications in research.

Positive

• Publication in Cell enhances credibility and visibility for NanoString's GeoMx DSP.
• Study utilized advanced techniques, reinforcing the product's scientific utility.
• GeoMx DSP has been featured in over 60 peer-reviewed publications, showcasing its effectiveness.

Negative

• None.

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced a peer-reviewed publication using the GeoMx^® Digital Spatial Profiler (DSP), published in the journal Cell.

Image: Current cover of the journal Cell (Graphic: Business Wire)

The study, “Spatially organized multicellular immune hubs in human colorectal cancer,” was led by Drs. Karin Pelka, Matan Hofree, and Jonathan Chen at the Broad Institute of MIT and Harvard. They used single cell transcriptomics, in situ hybridization, and GeoMx DSP to assess the mechanisms governing interactions between colorectal tumor cells and tumor-infiltrating immune cells.

The study investigated a cohort of 28 mismatch repair-proficient tumors and 34 mismatch repair-deficient colorectal cancer samples. In a subset of these tumors with a high number of potentially tumor-reactive T cells, the authors quantified cellular programs defined by single cell RNA-seq and mapped their interactions using the GeoMx Cancer Transcriptome Atlas (CTA) assay across 135 regions of interest, thus revealing the spatial transcriptional regulation that organizes immune-malignant cell networks. The auto segmentation capabilities of the DSP, which allows for tissue compartment-based profiling based on cellular phenotype, were essential to localizing transcriptional signatures to specific cell populations.

“To validate the interaction between malignant and T cell programs, we performed spatially-indexed transcript profiling on our patient tumor sections. We observed a positive correlation between interferon stimulated gene expression in malignant epithelial areas and CXCL13 expression in adjacent non-epithelial areas across all regions. From our single cell RNA-seq data we knew that CXCL13 was specifically expressed by chronically stimulated, potentially tumor-reactive T cells,” said Pelka. “These findings further support potential interactions between malignant cells and T cells in this hub via a chemokine mediated network,” added co-author Jonathan Chen, Massachusetts General Hospital.

“This study demonstrates the power of combining conventional single cell gene expression and GeoMx Digital Spatial Profiling enabled by Next Generation Sequencing readout,” said Brad Gray, NanoString’s president and chief executive officer.

The GeoMx DSP enables researchers to rapidly and quantitatively characterize tissue morphology with a high-throughput, high-plex RNA and protein profiling system that preserves precious samples for future analyses. NanoString and its collaborators have presented DSP data in dozens of abstracts at major scientific meetings and in more than 60 peer-reviewed publications, demonstrating DSP’s utility to address a wide range of biological questions in FFPE and frozen tissues. Interested parties can learn more about DSP by visiting https://www.nanostring.com/products/geomx-digital-spatial-profiler/geomx-dsp-overview/.

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company’s nCounter^® Analysis System is used in life sciences research and has been cited in more than 4,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company’s GeoMx^® Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

For more information, please visit https://www.nanostring.com/.

NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005275/en/

Doug Farrell, NanoString

Vice President, Investor Relations & Corporate Communications

dfarrell@nanostring.com

Phone: 206-602-1768

Source: NanoString Technologies, Inc.

FAQ

What is the significance of the study published by NanoString Technologies in the journal <i>Cell</i>?

The study highlights the application of NanoString's GeoMx DSP in understanding immune-tumor interactions in colorectal cancer and enhances the product's credibility.

How does the GeoMx Digital Spatial Profiler benefit cancer research?

The GeoMx DSP allows for high-throughput RNA and protein profiling, aiding researchers in characterizing tissue morphology and cellular interactions.

What did the study involving 28 mismatch repair-proficient tumors and 34 mismatch repair-deficient tumors reveal?

The study identified spatial transcriptional regulation in tumors, revealing how immune cells interact with malignant cells, which may inform future therapies.

Who led the study that utilized NanoString's GeoMx DSP?

The study was led by Drs. Karin Pelka, Matan Hofree, and Jonathan Chen from the Broad Institute of MIT and Harvard.